Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY<sub>3-36</sub>, and Empagliflozin on Early MASLD in Diet-Induced Obese Rats

(1) Background: Modulators of the Neuropeptide Y (NPY) system are involved in energy metabolism, but the effect of NPY receptor antagonists on metabolic-dysfunction-associated steatotic liver disease (MASLD), a common obesity-related comorbidity, are largely unknown. In this study, we report on the...

Full description

Bibliographic Details
Main Authors: Simon Kloock, Niklas Haerting, Gloria Herzog, Marie Oertel, Niklas Geiger, Andreas Geier, Vasco Sequeira, Alexander Nickel, Michael Kohlhaas, Martin Fassnacht, Ulrich Dischinger
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Nutrients
Subjects:
Online Access:https://www.mdpi.com/2072-6643/16/6/904